IPO Window Remains Open, But M&A Slows—Are Valuations Getting Too Frothy?

article image
ARTICLE SUMMARY:

Public investors maintained their interest in medtech—particularly small caps—in the first quarter of 2019, while M&A slowed. Could this be a sign that the sector’s rising valuations are causing prospective acquirers to back off?

If the first quarter US medtech M&A and IPO data are signs of how the rest of this year is going to play out, then the industry is looking at a classic good news/bad news performance.

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: